Prognose

Das durchschnittliche Kursziel der Analysten beträgt +32,95€(+59,95%). Der Median liegt bei +32,95€(+59,95%).

Kaufen	2
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement» Mehr auf globenewswire.com
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No.» Mehr auf globenewswire.com
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial Top-line results from SELVA remain on track for the first quarter of 2026 QTORIN™ 3.9% rapamycin anhydrous gel has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) was featured by Dr. Amy Paller in an oral presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Palvella Therapeutics Inc einen Umsatz von 0,00€ und ein Nettoeinkommen von −2,35 Mio€

(EUR)	März 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	-
Nettoeinkommen	−2,35 Mio	-
EBITDA	−1,60 Mio	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+238,33 Mio€
Anzahl Aktien	11,02 Mio
52 Wochen-Hoch/Tief	+25,72€ - +5,45€
Dividenden	Nein
Beta	-23,17
KGV (PE Ratio)	−3,14
KGWV (PEG Ratio)	−0,03
KBV (PB Ratio)	+0,88
KUV (PS Ratio)	0,00